OPT-302 Phase 2b study in wet AMD: A multicentre, randomised, double-masked, sham controlled study of intravitreal OPT-302 in combination with ranibizumab, in participants with wet AMD

    Activity: Talk or presentationOral presentation

    Period5 Sept 2019
    Event titleEURETINA: Annual meeting 2019
    Event typeConference
    LocationParis, FranceShow on map
    Degree of RecognitionInternational